Intramyocardial Delivery of Autologous Bone Marrow

Status Suspended

Clinical Trial Summary

A randomized study to assess the safety, feasibility and effectiveness of direct intramyocardial percutaneous delivery of autologous bone marrow-derived total mononuclear cells or selected CD34+ cells in patients with refractory angina pectoris.

Clinical Trial Description

Primary Endpoint: Incidence of major adverse cardiac events (MACE) at 30 days. MACE is defined as a combined endpoint of death, acute MI (Q-wave and non-Q wave), revascularization procedures (percutaneous or surgical), and peri-procedural complications (that is, left ventricular perforation with hemodynamic consequences requiring pericardiocentesis, and stroke).

Incidence of MACE at 3, 6 and 12 months

Secondary Endpoints:

- Change in Canadian Cardiovascular Society (CCS) angina classification score from baseline to 12 months

- Changes in the quality of life, as assessed according to the Seattle Angina Questionnaire

- Change in exercise duration and exercise tolerance using standardized treadmill exercise testing from baseline, to 6 months and to 12 months

- Cumulative number of hospitalizations for coronary ischemia and congestive heart failure at 12 months following treatment.

- SPECT-chances in global and regional radionuclide perfusion at rest, peak stress, and redistribution for baseline to 1, 6 and 12 months

- Change in angiographic collateral score at 6 months

- Change in global and regional myocardial contractility (assessed by echocardiography) at baseline, 6 and 12 months. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Refractory Angina

Clinical Trial Details

NCT number	NCT00820586
Study type	Interventional
Source	IRCCS San Raffaele
Contact
Status	Suspended
Phase	Phase 2
Start date	May 2007
Completion date	December 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01205893` - Coronary Sinus Reducer for Treatment of Refractory Angina - COSIRA	Phase 2
Suspended	`NCT04306237` - A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina	Phase 2
Recruiting	`NCT04892537` - Coronary Sinus Reducer Objective Impact on Symptoms, MRI Ischaemia and Microvascular Resistance	N/A
Completed	`NCT00694642` - Safety and Efficacy of Autologous Endothelial Progenitor Cell CD 133 for Therapeutic Angiogenesis	Phase 1/Phase 2
Recruiting	`NCT04368819` - Allopurinol in Patients With Refractory Angina to Improve Ischemic Symptoms	Phase 2/Phase 3
Recruiting	`NCT05711849` - Assessing the Safety and Effectiveness of Intracoronary Stem Cells in Patients With Refractory Angina	Phase 2
Recruiting	`NCT03455725` - CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial	N/A
Completed	`NCT01966042` - Study Protocol of Intramyocardial Injection of Autologous Bone Marrow Stem Cells for Refractory Angina	Phase 2
Recruiting	`NCT03991871` - HARapan kiTa ECP (External Counter Pulsation) Study HARTEC Study	N/A
Recruiting	`NCT05102019` - Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II	N/A
Completed	`NCT03218891` - Cardiac Rehabilitation in Patients With Refractory Angina	N/A
Completed	`NCT01796912` - Lipoprotein Apheresis in Refractory Angina Study	N/A
Completed	`NCT03350737` - Coronary Arteriogenetic Heparinized Exercise	N/A
Recruiting	`NCT01566175` - Use of the Neovasc Coronary Sinus Reducer System for the Treatment of Refractory Angina Pectoris in Patients With Ngina Class 3-4 Who Are Not Candidates for Revascularization	N/A
Recruiting	`NCT05492110` - Coronary Sinus Reducer Implantation in Patients With Ischaemia and Non-obstructed Coronary Arteries and Coronary Microvascular Dysfunction.	N/A
Recruiting	`NCT04606459` - COSIMA: COronary SInus Reducer for the Treatment of Refractory Microvascular Angina	N/A